scholarly journals Metabolic Alterations in Pancreatic Cancer Detected by In Vivo 1H-MR Spectroscopy: Correlation with Normal Pancreas, PET Metabolic Activity, Clinical Stages, and Survival Outcome

Diagnostics ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 1541
Author(s):  
Chih-Kai Chang ◽  
Tiffany Ting-Fang Shih ◽  
Yu-Wen Tien ◽  
Ming-Chu Chang ◽  
Yu-Ting Chang ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Metabolic Activity ◽  
Fdg Pet ◽  
Survival Outcome ◽  
Survival Outcomes ◽  
Normal Pancreas ◽  
Lipid Levels ◽  
1H Mrs ◽  
Clinical Stages

Objective: To compare the metabolites of in vivo 1H- MRS in pancreatic cancer with normal pancreas, and correlate these metabolites with Positron Emission Tomography (PET) metabolic activity, clinical stages, and survival outcomes. Methods: The prospective study included 58 patients (mean age 62.7 ± 12.1 years, range 34–81 years; 36 men, 22 women) with pathological proof of pancreatic adenocarcinoma, and all of them received 18F-fluorodeoxyglucose (FDG) PET/MRI before treatment. The single-voxel MRS with a point-resolved selective spectroscopy sequence was used to measure metabolites (creatine, Glx (glutamine and glutamate), N-acetylaspartate (NAA), and lipid) of pancreatic cancer and adjacent normal parenchyma, respectively. FDG-PET parameters included SUVmax, metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Non-parametric tests were used to evaluate the differences of MRS metabolites between pancreatic cancer and those in normal pancreas, and their correlation with PET parameters and clinical stages. The correlation with progression-free survival (PFS) and overall survival (OS) was measured using the Kaplan–Meier and Cox proportional hazard models. Results: When compared with normal pancreas, the Glx, NAA, and lipid levels were significantly decreased in pancreatic cancer (all p < 0.05). Creatine, Glx, and lipid levels were all inversely correlated with both MTV (rho = −0.405~−0.454) and TLG (rho = −0.331~−0.441). For correlation with clinical stages, lower lipid levels were found in patients with T4 (vs. <T4, p = 0.038) and lower creatine levels were found in N1 (vs. N0, p = 0.019). Regarding survival outcomes, high TNM stage, low creatine, low Glx, and low lipid levels were associated with both poor PFS and OS (all p < 0.05). Additionally, creatine remained an independent factor for PFS and OS after adjusting for age, sex, tumor size, stages, and other metabolites levels. Conclusions: Decreased MRS metabolites in pancreatic cancer were associated with poor survival outcome, and may be used as prognostic image biomarkers for these patients.

scholarly journals Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer

2016 ◽  
Vol 41 (3) ◽  
pp. 177-181 ◽  
Author(s):  
Jose M. Pimiento ◽  
Ashley H. Davis-Yadley ◽  
Richard D. Kim ◽  
Dung-Tsa Chen ◽  
Edward A. Eikman ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Metabolic Activity ◽  
Fdg Pet ◽  
Stage I ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Prediction of metastatic pancreatic cancer patients’ survival using both host immunity and tumor metabolic activity.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 411-411
Author(s):  
Younak Choi ◽  
Do-Youn Oh ◽  
Hyunkyung Park ◽  
Tae Yong Kim ◽  
Kyung-Hun Lee ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Risk Score ◽  
Metabolic Activity ◽  
Fdg Pet ◽  
Antitumor Immunity ◽  
Risk Groups ◽  
Host Immunity ◽  
Metastatic Pancreatic Cancer ◽  
Neutrophil Lymphocyte Ratio

411 Background: Host antitumor immunity measured by neutrophil-lymphocyte ratio (NLR) is reported to be associated with prognosis of cancer patients. Standard uptake value (SUV)by18F-FDG PET represents the metabolic activity of tumor itself. The correlation of host immunity and tumor metabolic activity has not been studied. We investigate the association of these two factors and evaluate their roles in prediction of overall survival (OS) in metastatic pancreatic cancer (MPC) patients who receive palliative chemotherapy. Methods: We reviewed 396 MPC patients receivingpalliative chemotherapy. NLR was obtained before initiation of chemotherapy and after 1st cycle of chemotherapy. In 118 patients who were evaluated with 18F-FDG PET before initiation of chemotherapy (PET cohort), maximum SUV (SUVmax) was collected. Cut-offs for each variable were determined by ROC curve. Results: In multivariate analysis, higher NLR was associated with worse OS ( < 2.5, 9.0 m; 2.5-4.4, 7.2 m; ≥ 4.5, 3.9 m; p< 0.001). Reduction of NLR after 1st cycle of chemotherapywas associated with betterOS (8.0 m vs 6.1 m; HR 0.653; p< 0.001). We made the risk scoring model considering both NLR (score 0, NLR < 2.5; score 1, 2.5 ≤ NLR < 4.5; score 2, NLR ≥ 4.5) and ΔNLR(score 0:ΔNLR < 0; score 1: ΔNLR ≥ 0), which identified 4 risk groups with different prognosis (group with risk score 0 vs 1 vs 2 vs 3: OS 9.7 vs 7.9 vs 5.7 vs 2.6 months; HR 1 vs 1.329 vs 2.137 vs 7.915, respectively; P < 0.001). In PET cohort (118 patients), NLR and SUVmax were independent prognostic factors for OS. The risk model considering both NLR (score 0, NLR < 2.5; score 1, 2.5 ≤ NLR < 4.5; score 2, NLR ≥ 4.5) and SUVmax (score 0:SUVmax < 4.5; score 1: SUVmax ≥ 4.5), which define 4 risk groups with different OS. (group with risk score 0 vs 1 vs 2 vs 3: OS 11.8 vs 9.8 vs 7.2 vs 4.6 months; HR 1 vs 1.536 vs 2.958 vs 5.336, respectively; P < 0.001). Conclusions: NLR and SUVmax as simple parameters of host antitumor immunity and tumor metabolic activity, respectively, have significant impacts on the survival of metastatic pancreatic cancer patients independently. Consideration of both aspects allows more precise prediction of patients’ prognosis.

The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy “In Vivo” in the Differential Diagnosis of Alzheimer’s Dementia

2019 ◽  
Vol 16 (7) ◽  
pp. 587-595 ◽  
Author(s):  
Roberto Santangelo ◽  
Alessandro Dell'Edera ◽  
Arianna Sala ◽  
Giordano Cecchetti ◽  
Federico Masserini ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Clinical Diagnosis ◽  
Fdg Pet ◽  
Amyloid Β ◽  
Cost Effective ◽  
Daily Clinical Practice ◽  
Different Types ◽  
Experimental Trials ◽  
Csf Findings

Background: The incoming disease-modifying therapies against Alzheimer’s disease (AD) require reliable diagnostic markers to correctly enroll patients all over the world. CSF AD biomarkers, namely amyloid-β 42 (Aβ42), total tau (t-tau), and tau phosphorylated at threonine 181 (p-tau181), showed good diagnostic accuracy in detecting AD pathology, but their real usefulness in daily clinical practice is still a matter of debate. Therefore, further validation in complex clinical settings, that is patients with different types of dementia, is needed to uphold their future worldwide adoption. Methods: We measured CSF AD biomarkers’ concentrations in a sample of 526 patients with a clinical diagnosis of dementia (277 with AD and 249 with Other Type of Dementia, OTD). Brain FDG-PET was also considered in a subsample of 54 patients with a mismatch between the clinical diagnosis and the CSF findings. Results: A p-tau181/Aβ42 ratio higher than 0.13 showed the best diagnostic performance in differentiating AD from OTD (86% accuracy index, 74% sensitivity, 81% specificity). In cases with a mismatch between clinical diagnosis and CSF findings, brain FDG-PET partially agreed with the p-tau181/Aβ42 ratio, thus determining an increase in CSF accuracy. Conclusions: The p-tau181/Aβ42 ratio alone might reliably detect AD pathology in heterogeneous samples of patients suffering from different types of dementia. It might constitute a simple, cost-effective and reproducible in vivo proxy of AD suitable to be adopted worldwide not only in daily clinical practice but also in future experimental trials, to avoid the enrolment of misdiagnosed AD patients.

In Vitro and In Vivo Antitumor Efficacy of Docetaxel and Sorafenib Combination in Human Pancreatic Cancer Cells

2010 ◽  
Vol 999 (999) ◽  
pp. 1-11
Author(s):  
P. Ulivi ◽  
C. Arienti ◽  
W. Zoli ◽  
M. Scarsella ◽  
S. Carloni ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Cells ◽  
Antitumor Efficacy ◽  
Human Pancreatic Cancer ◽  
Pancreatic Cancer Cells

EMAP II-Based Antiangiogenic-Antiendothelial In Vivo Combination Therapy of Pancreatic Cancer

2009 ◽  
Vol 17 (5) ◽  
pp. 1442-1452 ◽  
Author(s):  
Roderich E. Schwarz ◽  
Niranjan Awasthi ◽  
Srivani Konduri ◽  
Danielle Cafasso ◽  
Margaret A. Schwarz
Keyword(s):  
Pancreatic Cancer ◽  
Combination Therapy ◽  
Emap Ii

scholarly journals GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties

Biology ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 610
Author(s):  
Robin Park ◽  
Andrew L. Coveler ◽  
Ludimila Cavalcante ◽  
Anwaar Saeed
Keyword(s):  
Pancreatic Cancer ◽  
Therapeutic Potential ◽  
Glycogen Synthase ◽  
Glycogen Synthase Kinase ◽  
Glycogen Synthase Kinase 3 ◽  
In Vivo Models ◽  
Gsk 3Β ◽  
Early Phase Clinical Trials

Glycogen synthase kinase-3 beta is a ubiquitously and constitutively expressed molecule with pleiotropic function. It acts as a protooncogene in the development of several solid tumors including pancreatic cancer through its involvement in various cellular processes including cell proliferation, survival, invasion and metastasis, as well as autophagy. Furthermore, the level of aberrant glycogen synthase kinase-3 beta expression in the nucleus is inversely correlated with tumor differentiation and survival in both in vitro and in vivo models of pancreatic cancer. Small molecule inhibitors of glycogen synthase kinase-3 beta have demonstrated therapeutic potential in pre-clinical models and are currently being evaluated in early phase clinical trials involving pancreatic cancer patients with interim results showing favorable results. Moreover, recent studies support a rationale for the combination of glycogen synthase kinase-3 beta inhibitors with chemotherapy and immunotherapy, warranting the evaluation of novel combination regimens in the future.

scholarly journals The Revolutionary Roads to Study Cell–Cell Interactions in 3D In Vitro Pancreatic Cancer Models

Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 930
Author(s):  
Donatella Delle Cave ◽  
Riccardo Rizzo ◽  
Bruno Sainz ◽  
Giuseppe Gigli ◽  
Loretta L. del Mercato ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Therapeutic Response ◽  
Three Dimensional ◽  
Cellular Models ◽  
Common Cancer ◽  
Cancer Models ◽  
Anti Cancer ◽  
Tumor Environment

Pancreatic cancer, the fourth most common cancer worldwide, shows a highly unsuccessful therapeutic response. In the last 10 years, neither important advancements nor new therapeutic strategies have significantly impacted patient survival, highlighting the need to pursue new avenues for drug development discovery and design. Advanced cellular models, resembling as much as possible the original in vivo tumor environment, may be more successful in predicting the efficacy of future anti-cancer candidates in clinical trials. In this review, we discuss novel bioengineered platforms for anticancer drug discovery in pancreatic cancer, from traditional two-dimensional models to innovative three-dimensional ones.

Sign in / Sign up

Export Citation Format

Share Document